Overview
Services

TRANSGENIC GROUP INC.

Transgenic Group is a holding company operating two core segments: Drug Discovery Support and Investment & Consulting. The Drug Discovery Support segment provides seamless contract research services spanning early-stage exploratory research through non-clinical and clinical trials, including genetically modified mouse generation, antibody production, glycan analysis/synthesis, pharmacology/safety testing, and gene analysis. The Investment & Consulting segment, operated through TG Business Service Co., Ltd., drives new business development via M&A and provides advisory and support services in business succession and corporate revitalization across diverse sectors including electronics retail, e-commerce, information and communications equipment, glass materials, and packaging.

Market Cap
¥3.45B
US$22.0M
EV
¥3.69B
US$23.5M
Stock¥207▲+0.00%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
10.2
x
LTM EV/EBIT
14.3
x
LTM PER
104.5
x
LTM PBR
0.7
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-19.3%pt
10012
Oct 24, 25 – Oct 23, 26StockTOPIX
1Nov 27, 25Q3 earnings: upward revision, FY Op. profit up
2Aug 13, 26Q1 FY2027/03 earnings announced
MC → EV Bridge
3.45BUS$22.0MMarket Cap2.61BUS$16.7M+ Debt2.26BUS$14.4M− Cash0.17BUS$1.06M− Inv. Sec.0.06BUS$0.36M+ NCI3.69BUS$23.5MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
12.6US$80.2M'22/311.4US$72.9M'23/313.1US$83.4M'24/313.0US$82.9M'25/313.2US$84.0M'26/3
EBITDA 5Y (¥B)
1.99US$12.7M'22/30.10US$0.63M'23/30.19US$1.24M'24/3-0.12-US$0.76M'25/30.25US$1.57M'26/3
Net Income 5Y (¥B)
1.88US$12.0M'22/3-0.41-US$2.61M'23/30.00US$0.03M'24/3-1.09-US$6.95M'25/3-0.08-US$0.49M'26/3
Capital Structure
65%
35%
EquityD/E 0.54xDebt
Liquidity vs Debt 5Y (¥B)▼ Net Debt
CashInv. Sec.Debt
4.73US$30.2M1.82US$11.6M'22/33.56US$22.7M2.42US$15.4M'23/32.61US$16.6M2.22US$14.2M'24/32.66US$17.0M2.58US$16.5M'25/32.36US$15.0M2.10US$13.4M'26/3
Shareholders
Top 10 hold 11.9%
1
Tetsuro KOBAYASHI
1.86%
2
Yoshihisa UCHIDA
1.42%
3
Morgan Stanley MUFG Securities Co., Ltd.
1.39%
4
BNYM SA/NV FOR BNYM FOR BNY GCM CLIENT ACCOUNTS M LSCB RD
1.21%
5
Kenji FUKUNAGA
1.14%
6
Masaki FUJII
1.03%
7
Masaaki KUBOTA
1.02%
8
Nomura Securities Co., Ltd.
0.97%
9
Mutoh Co., Ltd.
0.96%
10
Ikuo HARADA
0.90%
Management
11 officers
Kenji FUKUNAGA
Representative Director, President
Oct 1993 Joined Tohmatsu Audit Corporation (currently Deloitte Tohmatsu LLC) Jun 1997 Registered as Certified Public Accountant May 2003 Director, Tohmatsu Venture Support Co., Ltd. (currently Deloitte Tohmatsu Venture Support Co., Ltd.) Aug 2006 Opened Fukunaga CPA and Tax Accountant Office, Representative Jun 2009 Joined the Company, Director Jun 2010 Representative Director, President of the Company (current) Apr 2013 Representative Director, President, Shinyaku Research Center Co., Ltd. (currently Transgenic Inc.) Nov 2017 Established TG Business Service Co., Ltd., Representative Director, President (current) Mar 2018 Established Anhyo Center Co., Ltd. (currently Transgenic Inc.), Representative Director, President; Transgenic Inc. Oct 2024 Representative Director, Chairman Mar 2026 Director, Transgenic Inc. (current)
1969-08-13
Shunichi KITAJIMA
Director, CRO Business Division Head and Facility Operations Office Manager
Apr 1987 Joined Panafarm Laboratories Co., Ltd. (currently LSI Medience Corporation) Oct 1999 Director, Primate Co., Ltd. Oct 2003 Established Bio Lab Co., Ltd., Director Jul 2007 Specially Appointed Lecturer, Hyogo Medical University Apr 2008 Director, GMJ Co., Ltd. Sep 2011 Joined the Company, Head of New Business Division (currently CRO Business Division Head) Apr 2013 Director, Shinyaku Research Center Co., Ltd. (currently Transgenic Inc.) Jun 2015 Director, CRO Business Division Head of the Company (current) Apr 2016 Director, Facility Operations Office Manager, Group Administration Division of the Company Mar 2018 Director, Anhyo Center Co., Ltd. (currently Transgenic Inc.) Apr 2021 Director, Facility Operations Office Manager of the Company (current) Jun 2023 Director in charge of Group R&D Coordination Office of the Company (current) Director, Transgenic Inc. (current) Oct 2024
1960-01-31
Yasushi FUNABASHI
Director, IR and Corporate Administration Office Manager, Information Management Office Manager and General Manager of General Affairs and Human Resources Department
Nov 2002 Joined the Company Apr 2010 General Manager, Corporate Planning Department of the Company Sep 2010 General Manager, Corporate Planning Department and General Manager, Administration Department of the Company Jun 2011 Director of the Company Apr 2013 Director, Shinyaku Research Center Co., Ltd. (currently Transgenic Inc.) Apr 2015 Part-time Lecturer, Tokyo Institute of Technology Graduate School Jun 2015 Director, Corporate Planning Office Manager and Information Management Office Manager, Group Administration Division of the Company Apr 2016 Director, General Manager, General Affairs and Human Resources Department, Group Administration Division of the Company Jun 2016 Audit & Supervisory Board Member, Shinyaku Research Center Co., Ltd. (currently Transgenic Inc.) Nov 2017 Director, TG Business Service Co., Ltd. (current) Mar 2018 Audit & Supervisory Board Member, Anhyo Center Co., Ltd. (currently Transgenic Inc.) Apr 2021 Director, IR and Corporate Administration Office Manager and Information Management Office Manager of the Company (current) Audit & Supervisory Board Member, Transgenic Inc. Oct 2024 Director, Transgenic Inc. (current) Jun 2025 Director, General Manager of General Affairs and Human Resources Department of the Company (current) Apr 2026
1973-12-14
Kazuo WATANABE
Director, General Manager of Accounting and Finance Department
Apr 1991 Joined Yasuda Trust & Banking Co., Ltd. (currently Mizuho Trust & Banking Co., Ltd.) Oct 2001 Joined Tohmatsu Audit Corporation (currently Deloitte Tohmatsu LLC) May 2005 Registered as Certified Public Accountant Jul 2013 Transferred to Tohmatsu Tax Corporation (currently Deloitte Tohmatsu Tax Co.) Dec 2013 Registered as Certified Tax Accountant Jul 2017 Joined the Company, General Manager, Accounting and Finance Department Nov 2017 Director, TG Business Service Co., Ltd. (current) Mar 2018 Director, Anhyo Center Co., Ltd. (currently Transgenic Inc.) Jun 2018 Director, General Manager of Accounting and Finance Department of the Company (current) Oct 2024 Director, Shinyaku Research Center Co., Ltd. (currently Transgenic Inc.) Director, Transgenic Inc. (current)
1967-12-10
Koji TAKASHIMA
Director
Apr 1981 Joined Nippon Express Co., Ltd. Aug 1985 Joined Bozo Research Center Co., Ltd. Apr 2014 Executive Officer, Bozo Research Center Co., Ltd., in charge of First Sales Division and Research Planning Department Feb 2023 Joined Anhyo Center Co., Ltd. (currently Transgenic Inc.), Deputy General Manager, Business Promotion Division Jun 2023 Director, General Manager, Business Promotion Division, Anhyo Center Co., Ltd. (currently Transgenic Inc.) Jun 2024 Director of the Company in charge of Drug Discovery Support Business (Business Promotion) (current) Oct 2024 Representative Director, President, Transgenic Inc. (current)
1958-12-15
Akihito TOMITA
Director, General Manager of Group Business Promotion Department
Oct 1998 Joined Tohmatsu Audit Corporation (currently Deloitte Tohmatsu LLC) May 2002 Registered as Certified Public Accountant Aug 2021 Joined the Company, Deputy General Manager, Group Business Promotion Department Jun 2023 Director, TG Business Service Co., Ltd. (current) Jun 2024 Director, General Manager of Group Business Promotion Department of the Company (current) Audit & Supervisory Board Member, Transgenic Inc. (current) Jun 2025
1973-11-14
Tsutomu SEITO
Director
Sep 1964 Technical Official, Division of Pathology, National Cancer Center Research Institute Apr 1975 Technical Official, First Department of Pathology, School of Medicine, Niigata University Sep 1978 Joined Japan Antibody Research Laboratories, Ltd. (currently JIMRO Co., Ltd.) Sep 1982 Established Immuno-Biological Laboratories Co., Ltd., Representative Director, President (current) Mar 2001 Established Genetechno Science Co., Ltd. (currently Kidswell Bio Co., Ltd.), Representative Director Aug 2009 Representative Director, Neosilk Co., Ltd. Jun 2011 Outside Director of the Company (current) Jul 2013 Representative Director, Chairman, Skylight Biotech Inc. Feb 2021 Representative Director, President, AI Bio Inc. (current)
1944-09-29
Hodaka SAITO
Director
Apr 1983 Joined Mitsubishi Kasei Corporation Jun 1983 Joined Mitsubishi Kasei Safety Science Research Institute Co., Ltd. Jul 1988 Visiting Associate Professor, Department of Environmental Science and Technology, Tokyo Institute of Technology (concurrent) Sep 2003 General Manager, Ecological Science Division, Mitsubishi Kasei Safety Science Research Institute Co., Ltd. Jul 2004 Director, Yokohama Research Institute, Mitsubishi Kasei Safety Science Research Institute Co., Ltd. Apr 2009 General Manager, Administration Department, Anken Business Division, and Director, Yokohama Research Institute, Mitsubishi Chemical Medience Corporation Jul 2010 General Manager, Corporate Planning Department, Mitsubishi Chemical Medience Corporation Jul 2014 Executive Officer, General Manager, Corporate Planning Department, LSI Medience Corporation Feb 2015 Executive Officer, General Manager, Corporate Planning Department and CSO, Life Science Institute, Inc. Apr 2016 Executive Officer, Head of Drug Discovery Support Business Division, LSI Medience Corporation Apr 2021 Senior Consultant, Mitsubishi Chemical Research Corporation Jun 2021 Outside Director of the Company (current) Jun 2024 Specially Appointed Researcher, Mitsubishi Chemical Research Corporation (current)
1958-01-08
Ryoji TOMONAGA
Full-time Audit & Supervisory Board Member
Oct 1982 Joined Tohmatsu & Co. (currently Deloitte Tohmatsu LLC) Apr 1986 Registered as Certified Public Accountant May 1993 Deloitte & Touche, New York Office (returned Jul 1997) Aug 2001 Registered as Certified Tax Accountant; opened Ryoji Tomonaga CPA and Tax Accountant Office, Representative May 2002 Joined Tohmatsu Tax Corporation (currently Deloitte Tohmatsu Tax Co.) Aug 2018 Opened Tomonaga CPA Office, Representative (current) Jun 2020 Outside Audit & Supervisory Board Member of the Company (current)
1958-03-12
Takao SATO
Audit & Supervisory Board Member
Apr 1995 Registered as Attorney at Law (Daini Tokyo Bar Association) Apr 2001 Opened Takao Sato Law Office Apr 2006 Part-time Lecturer, Keio University Graduate School of Law (current) Apr 2008 Civil Conciliation Commissioner, Tokyo Summary Court (current) Jun 2008 Outside Audit & Supervisory Board Member of the Company (current) May 2009 Outside Audit & Supervisory Board Member, Fund Creation Group Co., Ltd. Oct 2011 Attorney at Law, Kasumigaseki Law and Accounting Office Feb 2013 Outside Director, Fund Creation Group Co., Ltd. (current) Mar 2015 Attorney at Law, Sakuradadori Sogo Law Office (current)
1963-08-05
Masafumi HONBO
Audit & Supervisory Board Member
Apr 1979 Joined Minami-Kyushu Coca-Cola Bottling Co., Ltd. Jan 1998 General Manager, Accounting Department, the same company Apr 2001 Director, General Manager, Finance Department, the same company Apr 2006 Managing Director, General Manager, Management Planning Office, the same company Apr 2010 Managing Director, General Manager, Sales Division, the same company Sep 2012 Representative Director, President, MCA Holdings Inc. Mar 2013 Representative Director, President, VinEx Yamaga Co., Ltd. (currently Yamaga Distillery Co., Ltd.) (current) Sep 2019 Representative Director, Chairman, Takahata Winery Co., Ltd. Jun 2020 Outside Audit & Supervisory Board Member of the Company (current) Sep 2020 Director, Chairman, Takahata Winery Co., Ltd. Sep 2022 Representative Director, Chairman, Tazono Shuzo Co., Ltd. Mar 2023 Representative Director, Chairman and President, Tazono Shuzo Co., Ltd. Sep 2023 Director, Takahata Winery Co., Ltd. Sep 2024 Director, Chairman, MCA Holdings Inc. (current) Director, Chairman, Tazono Shuzo Co., Ltd. (current) Sep 2025
1955-05-27
Large Shareholding Reports
No filings
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-12
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-17
Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2026-02-10
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-11-13
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2025-08-12
Q1 Earnings Flash
FY ending Mar 2026
EDINETAmended
2025-08-01
Amended Annual Securities Report
Period: Apr 2024 – Mar 2025
EDINET
2025-06-30
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-14
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-13
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-09
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-21
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-13
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-13
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-14
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-22
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-13
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-14
Quarterly Securities Report
EDINET
2022-08-12
Quarterly Securities Report
EDINET
2022-06-24
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-15
Quarterly Securities Report
EDINET
2021-08-13
Quarterly Securities Report
EDINET
2021-06-24
Annual Securities Report
EDINET
2021-02-15
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →